NCT00861809View on ClinicalTrials.gov

The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Gastroparesis

Interventions

DRUG

GSK962040 25 mg

25 mg

DRUG

Placebo

placebo comparator

DRUG

GSK962040 50 mg

50 mg

DRUG

GSK962040 1250 mg

125 mg

Trial Locations (2)

3000

GSK Investigational Site, Leuven

SE-171 76

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY